AHPA on USP ingredient information
This article was originally published in The Tan Sheet
Executive Summary
The American Herbal Products Association asks U.S. Pharmacopoeia to "refrain from requiring cautionary statements" on "USP-quality black cohosh and USP powdered decaffeinated green tea extract" in its newly adopted ingredient safety classification system. Instead, AHPA suggests USP use a safety information section in supplement ingredient monographs to present findings from DSI-EC. This would allow manufacturers "to intelligently apply the findings of the DSI-EC as is appropriate on a product-by-product basis," the group says. The current system adopted by USP classifies ingredients into three categories: Class 1, (safe with no labeling statement), Class 2 (safe with suitable labeling statement) and Class 3 (not safe)...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.